The NIH-funded Diabetic Retinopathy Clinical Research Network is starting patient enrollment in August for a clinical study on the comparative effectiveness of Genentech Inc.’s products Lucentis (ranibizumab) and Avastin (bevacizumab) and Regeneron’s Eylea (aflibercept) in diabetic macular edema (DME), a sight-threatening complication of diabetes.
While the study will focus on the clinical effectiveness and safety of these treatments and is not designed as cost-effectiveness trial, the disparity in cost for these treatments is cited...